New Delhi, September 26: A recent report from the Central Drugs Standard Control Organization (CDSCO) has revealed that 53 medicines. Including commonly used drugs like Paracetamol and Pan D, have failed quality tests conducted by drug regulators. The findings have raised serious concerns about the safety and efficacy of these medications, prompting calls for stricter quality control measures and increased vigilance from both regulators and consumers.
Among the 53 non-compliant medicines, Paracetamol, a widely used pain reliever, and Pan D. A popular antacid, found to have failed quality tests. Other affected drugs included antibiotics, anti-hypertensives, and anti-diabetic medications. The specific reasons for the failures varied, ranging from incorrect labeling to substandard ingredients.
Vitamin C and D3 tablets Shelcal, vitamin B complex and vitamin C softgels, antiacid Pan-D, Paracetamol tablets IP 500 mg, anti-diabetic drug Glimepiride, high blood pressure drug Telmisartan, and many more are among the 53 top-selling drugs that failed the quality check by the drug regulator.
The CDSCO has taken action against the manufacturers of the non-compliant medicines, issuing show-cause notices and initiating investigations. If found guilty, the manufacturers could face penalties, including fines and suspension of their manufacturing licenses.
The revelations have sparked widespread concern among healthcare professionals and consumers. The failure of commonly used drugs to meet quality standards poses a significant risk to public health, as patients may be unknowingly consuming ineffective or even harmful medications.
The CDSCO has urged consumers to be vigilant and to check the authenticity of medicines before purchasing them. It has also advised patients to report any adverse reactions or concerns to the drug regulator.
The incident highlights the need for stricter quality control measures in the pharmaceutical industry. The CDSCO has called for increased investment in drug testing facilities and the strengthening of regulatory oversight.
In addition to regulatory measures, there is also a need for greater transparency and accountability from pharmaceutical companies. Manufacturers should required to disclose information about the quality of their products and to take responsibility for any failures.
The failure of 53 medicines (including pan D) to pass quality tests is a serious matter that cannot be ignored. It is imperative that the government and the pharmaceutical industry take swift and decisive action to address the issue and ensure the safety and efficacy of medicines available to Indian consumers.
Read Also – Serum Institute of India Developing Mpox Vaccine, Confirms CEO Adar Poonawalla
In August, the CDSCO banned over 156 fixed-dose drug combinations in the Indian market that are “likely to involve risk to humans”. These medicines included popular fever drugs, painkillers and allergy tablets.
